Oncology

New skin cancer combination therapy more effective than current treatments.

Oraxol is combination P-glycoprotein pump inhibitor and an oral version of paclitaxel.

Athenex and Eli Lilly partner to conduct a phase 1b trial for experimental cancer drug.

Majority of people with chronic hepatitis C are unaware of the infection.

Mouth cancer rates show significant increase among males and females of all ages.

Partnership between Clearbrdige BioMedics and John Wayne Cancer Institute will initially focus on melanoma.

Trained clinical pharmacists can effectively manage patients with hepatitis C virus.

Have you ever considered pursuing a post-graduate year 2 pharmacy residency in oncology?

Trisenox is the first approved acute leukemia treatment that is chemotherapy-free.

Reovirus may treat primary liver cancer and hepatitis C virus.

The new method makes breast imaging less risky, and can lessen false-positive readings.

New treatments show promise harnessing the immune system to attack late-stage skin cancer.

Trametinib targets a type of immune cell that inhibits T cell response in cancer.

Top news of the day from across the health care landscape.

A novel drug used in combination with radiation found to be a more effective treatment for prostate cancer.

About 1 in 6 women diagnosed with breast cancer have a symptom other than a lump.

New findings show that treatment with cabozantinib decreased mortality risk by 20% in patients with metastatic kidney cancer.

Increased levels of tumor-associated myeloid cells reduce cancer cell sensitivity to treatments.

Women who display non-lump breast cancer symptoms are less likely to seek needed care.

Determining the contents of extracellular vesicles may create targeted treatments.

Different hepatitis C genotypes are more prominent in certain areas than others.

Tailored dose-dense chemotherapy did not statistically improve recurrence-free survival in breast cancer patients.

Top news of the week in oncology and cancer drug development.

A more personalized surveillance approach may help catch melanomas in high-risk patients.

Gene therapy stimulates blood vessel growth in the heart to avoid cancer drug side effects.

Targeting a certain antioxidant protein reduces the aggressiveness of triple-negative breast cancer and increases its sensitivity to conventional anti-cancer drugs.

IL-1 antagonists are traditionally used to treat patients with rheumatoid diseases.

Targeted personalized therapy in patients with diabetes can reduce the risk of developing cancer.